David A. Amato

TL;DR: Eszopiclone/fluoxetine co-therapy was relatively well tolerated and associated with rapid, substantial, and sustained sleep improvement, a faster onset of antidepressant response on the basis of CGI, and a greater magnitude of the antidepressant effect.

TL;DR: Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function, which is compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.

TL;DR: This is the first placebo-controlled investigation to demonstrate that long-term nightly pharmacologic treatment of primary insomnia with any hypnotic enhanced quality of life, reduced work limitations, and reduced global insomnia severity, in addition to improving patient-reported sleep variables.

TL;DR: Ezopiclone was well tolerated in elderly patients with primary insomnia, and the sleep efficacy was accompanied by significantly less napping and significantly higher ratings of daytime alertness, sense of physical well-being, and several quality-of-life parameters at the higher dose.

TL;DR: Patients treated with nightly eszopiclone 3 mg had better polysomnographic and patient-reported measures of sleep over the 6-week trial and no detrimental effects on next-day psychomotor performance using the DSST.